Abstract
Ninety-two patients with advanced non-small cell lung cancer were treated with a combination chemotherapy regimen containing cisplatin, vindesine, and etoposide. Eighteen patients (20%) achieved major responses to therapy (three complete responders and 15 partial responders). Response rates were similar in each histologic subtype. Initial performance status was an important determinant of response; 42% of the patients with a Karnofsky performance status ≥70% responded versus 5% of those with a performance status <50%. The median duration of partial response was 21 weeks; complete responders had a median response duration of 50 weeks. The median survival for the entire group was 23.5 weeks. Toxicity with this regimen was acceptable; myelosuppression was the major toxic effect and was severe in only 10% of the patients. This regimen produced response rates comparable to those reported with other combinations containing cisplatin. Survival advantage in patients receiving this treatment is not established.
Original language | English (US) |
---|---|
Pages (from-to) | 339-341 |
Number of pages | 3 |
Journal | Cancer treatment reports |
Volume | 70 |
Issue number | 3 |
State | Published - 1986 |
ASJC Scopus subject areas
- Oncology
- Cancer Research